The present disclosure generally relates to the treatment of subjects having osteoarthritis or at risk of developing osteoarthritis by administering a Procollagen Galactosyl Transferase 2 (COLGALT2) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
2.
RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL
The present invention generally pertains to methods of enriching an antibody of interest. In particular, the present invention pertains to the use of Protein A chromatography in the form of a centrifugal column to enrich a therapeutic antibody from an upstream cell culture process for product quality attribute profiling.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
3.
Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors
The present disclosure generally relates to the treatment of subjects having liver disease or metabolic disorder or at risk of developing liver disease or metabolic disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Disclosed herein are delivery devices for delivering a volume of a drug product, placebo product, or other product including a fluid. The devices may include a barrel having a longitudinal axis, a proximal end region, and a distal end region. The proximal end region may include an opening, and the barrel may be configured to receive a drug therein. A plunger rod may be disposed at least partially inside the barrel and protruding from the opening. The plunger rod may include a rack having a plurality of teeth. The device may further include a pinion having a plurality of teeth configured to engage with the plurality of teeth of the rack, and rotation of the pinion against the rack may move at least a part of the plunger rod along the longitudinal axis of the barrel.
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.
The disclosure provides gap junction protein beta 2 (GJB2) promoters and enhancers, as well as vectors containing the same, that can be used to express an expression product in GJB2-expressing cells, including cochlear supporting cells. The GJB2 promoters and enhancers described herein may be operably linked to a polynucleotide, such as a transgene encoding a wild-type form of Gjb2, for treatment of subjects having or at risk of developing hearing loss (e.g., GJB2-related hearing loss).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure generally relates to the treatment of subjects having macular degeneration or at risk of developing macular degeneration by administering a Complement Factor D (CFD) inhibitor to the subject, and to methods of identifying subjects having an increased risk of developing macular degeneration.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
8.
RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL
The present invention generally pertains to methods of enriching an antibody of interest. In particular, the present invention pertains to the use of Protein A chromatography in the form of a centrifugal column to enrich a therapeutic antibody from an upstream cell culture process for product quality attribute profiling.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
10.
TREATMENT OF MACULAR DEGENERATION WITH COMPLEMENT FACTOR D (CFD) INHIBITORS
The present disclosure generally relates to the treatment of subjects having macular degeneration or at risk of developing macular degeneration by administering a Complement Factor D (CFD) inhibitor to the subject, and to methods of identifying subjects having an increased risk of developing macular degeneration.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
11.
Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Variants And Uses Thereof
Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
12.
High Concentration VEGF Receptor Fusion Protein Containing Formulations
The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present inventions provide covalently surface modified adeno-associated viruses can comprise gene of interest (GOIs) and advantageously can be targeted to certain cell and tissue types for preventative and therapeutic purposes. The present inventions further provide systems and methods for engineering adeno-associated virus (AAV) to create covalently surface modified adeno-associated viruses, and methods of purifying such covalently surface modified adeno-associated viruses. The inventions further include covalently surface modified adeno-associated viruses and preparations and products comprising such covalently surface modified adeno-associated viruses.
The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a PD1 inhibitor (e.g., an anti-PD1 antibody). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
15.
METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAXCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a TAAxCDS bispecific antibody. The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Combination drug delivery devices sold full containing pharmaceutical preparations for the treatment of retinal diseases;
(2) Combination drug delivery devices sold empty for the treatment of retinal diseases;
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Combination drug delivery devices sold full containing pharmaceutical preparations for the treatment of retinal diseases. Combination drug delivery devices sold empty for the treatment of retinal diseases.
18.
Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors
The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
19.
METHODS OF TREATING CANCER WITH A COMBINATION OF A PD1 INHIBITOR AND A TARGETED IMMUNOCYTOKINE
The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a PD1 inhibitor (e.g., an anti-PD1 antibody). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
20.
METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1) in combination with a TAAxCD3 bispecific antibody. The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival of the subject, as compared to a subject administered the targeted immunocytokine as monotherapy.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A drug delivery device is disclosed, wherein the device comprises a housing; a cap located at a proximal end of the housing, the cap including a first pair of deflectable arms and a second pair of deflectable arms; a product vessel arranged in the housing, and a needle coupled to a distal end of the product vessel; a plunger rod for dispensing a product from the product vessel, wherein the plunger rod is slidably received within the cap and partially disposed inside the product vessel; and a needle cover at least partially disposed in the housing, wherein the first pair of deflectable arms are configured to deflect radially inwards towards the plunger rod and the second pair of deflectable arms are configured to radially outwards away from the plunger rod.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Methods and systems data down-sampling are disclosed. A method includes selecting data samples from a first set of data samples, each associated with a sampling date, that meet at least one quality control criterion to generate a second set of data samples, and down-sampling the second set of data samples into a plurality of subsets of data samples. Each subset of the plurality of subsets of data samples contains a data sample predetermined quantity and is associated with a different time period. Down-sampling includes generating, based on the sampling date, a sampling date distribution for the second set of data samples, and selecting, for each time period of the plurality of sequential time periods, based on the sampling date distribution, data samples from the second set of data samples until each subset of the plurality of subsets of data samples contains the predetermined quantity of data samples.
Methods and systems data down-sampling are disclosed. A method includes selecting data samples from a first set of data samples, each associated with a sampling date, that meet at least one quality control criterion to generate a second set of data samples, and down-sampling the second set of data samples into a plurality of subsets of data samples. Each subset of the plurality of subsets of data samples contains a data sample predetermined quantity and is associated with a different time period. Down-sampling includes generating, based on the sampling date, a sampling date distribution for the second set of data samples, and selecting, for each time period of the plurality of sequential time periods, based on the sampling date distribution, data samples from the second set of data samples until each subset of the plurality of subsets of data samples contains the predetermined quantity of data samples.
Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present inventions relate to improved lyophilization methods for therapeutic proteins, such as monoclonal antibodies, using controlled nucleation. The controlled nucleation approach is time efficient, and produces lyophilized products with high quality and faster reconstitution times. The present inventions also relate to efficient lyophilization process to achieve moderate moisture content in room temperature stable therapeutic proteins.
F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
A61K 9/19 - Particulate form, e.g. powders lyophilised
A drug delivery device is disclosed, wherein the device comprises a housing; a cap located at a proximal end of the housing, the cap including a first pair of deflectable arms and a second pair of deflectable arms; a product vessel arranged in the housing, and a needle coupled to a distal end of the product vessel; a plunger rod for dispensing a product from the product vessel, wherein the plunger rod is slidably received within the cap and partially disposed inside the product vessel; and a needle cover at least partially disposed in the housing, wherein the first pair of deflectable arms are configured to deflect radially inwards towards the plunger rod and the second pair of deflectable arms are configured to radially outwards away from the plunger rod.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The present inventions relate to improved lyophilization methods for therapeutic proteins, such as monoclonal antibodies, using controlled nucleation. The controlled nucleation approach is time efficient, and produces lyophilized products with high quality and faster reconstitution times. The present inventions also relate to efficient lyophilization process to achieve moderate moisture content in room temperature stable therapeutic proteins.
The present disclosure relates to chimeric heavy chain constant domains having reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Nucleic acids encoding such recombinant polypeptides are also disclosed, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
29.
METHODS FOR ALTERING BODY COMPOSITION BY ADMINISTERING A GDF8 INHIBITOR AND AN ACTIVIN A INHIBITOR
The present invention relates to compositions and methods for altering body composition in a subject, wherein the alteration of body composition is an increase in muscle mass and a reduction of fat mass simultaneously. The present invention also relates to compositions and methods for reducing fat mass in a subject. The compositions and methods also increase muscle volume and lean body mass in the subject. The present invention also relates to compositions that comprise a GDF8 inhibitor and an Activin A inhibitor and the use of such compositions to treat diseases and disorders characterized by increased fat mass, and/or decreased muscle volume.
The present inventions relate to improved and enhanced chromatographic systems for analyzing DNA, such as DNA released from AAV virions. The present inventions avoid past problems through the use of larger pore size media, different column flow rates and buffers comprising surfactants and increased concentrations of inorganic salts, and typically have column pressures of about 1450 to about 1550 psi.
The present inventions relate to improved and enhanced chromatographic systems for analyzing DNA, such as DNA released from AAV virions. The present inventions avoid past problems through the use of larger pore size media, different column flow rates and buffers comprising surfactants and increased concentrations of inorganic salts, and typically have column pressures of about 1450 to about 1550 psi.
Provided herein are methods of treating a subject with hyperammonemia or a urea cycle disorder. The methods comprise administering to a subject in need thereof a therapeutic amount of a glucagon signaling pathway inhibitor, such that ammonia levels are lowered or that amino acid metabolism enzymes are down-regulated, or a condition or disease characterized by hyperammonemia is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The glucagon signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, shRNA, siRNA, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from hyperammonemia or a urea cycle disorder.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
34.
METHODS FOR OBTAINING ANTIBODY MOLECULES BINDING TO A PEPTIDE-MHC INTERFACE
Disclosed herein are methods for isolating antibody-producing cells that express antibody molecules specific for an interface between a target peptide and an MHC molecule. The methods disclosed herein utilize a blocking reagent when sorting cells such as splenocytes which permits enrichment of cells expressing rare antibody molecules that specifically recognize an MHC-peptide interface.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
C07K 14/74 - Major histocompatibility complex [MHC]
Disclosed herein are methods for isolating antibody-producing cells that express antibody molecules specific for an interface between a target peptide and an MHC molecule. The methods disclosed herein utilize a blocking reagent when sorting cells such as splenocytes which permits enrichment of cells expressing rare antibody molecules that specifically recognize an MHC-peptide interface.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
37.
TREATMENT OF OSTEOARTHRITIS WITH CARTILAGE INTERMEDIATE LAYER PROTEIN 2 (CILP2) INHIBITORS
The present disclosure generally relates to the treatment of subjects having osteoarthritis or at risk of developing osteoarthritis by administering a Cartilage Intermediate Layer Protein 2 (CILP2) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
38.
METHODS AND SYSTEMS FOR DEVELOPING CHROMATOGRAPHY PROTOCOLS
A method of purifying a target molecule may include introducing a load including a high molecular weight species concentration (%HMW) to a chromatography apparatus comprising sartobind phenyl chromatography media. A method of generating a chromatography protocol, may include identifying chromatography loading parameters, identifying chromatography performance criteria. The method of generating the chromatography protocol may include selecting combinations of test values of the loading parameters, and conducting a chromatography run for each combination of the set of test values combinations, thereby generating actual performance criteria values corresponding to each combination of the set of test value combinations.
C07K 1/16 - ExtractionSeparationPurification by chromatography
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
The present disclosure provides isolated peptides derived from human T-lymphotropic virus type-1 (HTLV-1), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treatment, prevention, or reduction of the likelihood of HTLV-1 infection and/or HTLV-1 -induced diseases. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treatment, prevention, or reduction of the likelihood of HTLV-1 infection and/or HTLV-1 -induced diseases. The present disclosure further provides methods and systems for identifying immunogenic virus-derived peptides.
A61K 39/385 - Haptens or antigens, bound to carriers
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex [MHC]
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
40.
KRAS10-18 G12D OFF-TARGET PEPTIDES AND USES THEREOF
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex [MHC]
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand 1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
42.
IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer
The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting and administering to a subject in need thereof a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In certain embodiments, the IL-4/IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
43.
Treatment Of Osteoarthritis With Cartilage Intermediate Layer Protein 2 (CILP2) Inhibitors
The present disclosure generally relates to the treatment of subjects having osteoarthritis or at risk of developing osteoarthritis by administering a Cartilage Intermediate Layer Protein 2 (CILP2) inhibitor to the subject.
A method of purifying a target molecule may include introducing a load including a high molecular weight species concentration (% HMW) to a chromatography apparatus comprising sartobind phenyl chromatography media. A method of generating a chromatography protocol, may include identifying chromatography loading parameters, identifying chromatography performance criteria. The method of generating the chromatography protocol may include selecting combinations of test values of the loading parameters, and conducting a chromatography run for each combination of the set of test values combinations, thereby generating actual performance criteria values corresponding to each combination of the set of test value combinations.
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
The present disclosure provides chimeric antigen receptors (CARs) targeting MUC16, genetically modified immune effector cells, and use of these compositions to treat cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
46.
METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
Methods for treating moderate-to-severe or severe atopic dermatitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
47.
METHODS AND SYSTEMS FOR ASSESSING CHROMATOGRAPHIC COLUMN INTEGRITY
A method for assessing chromatographic column integrity may include introducing acetone into a chromatographic column and measuring absorbance values of an eluate of the chromatographic column. The method for assessing chromatographic column integrity may also include generating a first data structure based on the absorbance values, implementing a fitting algorithm based on the first data structure to generate a transition function, generating a second data structure based on the transition function, and generating a transition plot based on the first and second data structures, wherein the transition plot includes transition plot-related data. A value of a performance parameter may be generated based on the transition plot-related data.
A method for assessing chromatographic column integrity may include introducing acetone into a chromatographic column and measuring absorbance values of an eluate of the chromatographic column. The method for assessing chromatographic column integrity may also include generating a first data structure based on the absorbance values, implementing a fitting algorithm based on the first data structure to generate a transition function, generating a second data structure based on the transition function, and generating a transition plot based on the first and second data structures, wherein the transition plot includes transition plot-related data. A value of a performance parameter may be generated based on the transition plot-related data.
The present disclosure generally relates to the treatment of subjects having acne rosacea or at risk of developing acne rosacea by administering a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
50.
PRODUCTION AND PURIFICATION OF COVALENTLY SURFACE MODIFIED ADENO-ASSOCIATED VIRUS
The present inventions provide covalently surface modified adeno-associated viruses can comprise gene of interest (GOIs) and advantageously can be targeted to certain cell and tissue types for preventative and therapeutic purposes. The present inventions further provide systems and methods for engineering adeno-associated virus (AAV) to create covalently surface modified adeno-associated viruses, and methods of purifying such covalently surface modified adeno-associated viruses. The inventions further include covalently surface modified adeno-associated viruses and preparations and products comprising such covalently surface modified adeno- associated viruses.
C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C12N 15/62 - DNA sequences coding for fusion proteins
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical research services, namely, nucleic acid molecule development and nucleic acid molecule delivery development and production; genetic engineering services utilizing a collection of genetic technologies for the production and delivery of immune modulators; scientific, laboratory and medical research in the field of genetic engineering technologies; scientific laboratories performing nucleic acid molecule development and nucleic acid molecule delivery development; scientific research and development, namely, development of nucleic acid molecule and nucleic acid molecule delivery for others
Methods can be conducted to prevent disulfide scrambling in liquid chromatography-mass spectrometry analysis of a protein of interest. In particular, methods can be conducted by employing a NEM analog, such as maleimide, and a heavy isotope counterpart of the NEM analog, such as a heavy isotope substituted maleimide, to alkylate a protein of interest and to alkylate a peptide digest of the protein of interest under conditions that prevent disulfide scrambling and subjecting the samples to a liquid chromatography-mass spectrometry analysis.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing cells that have been modified to express a first isoform of a target protein (e.g., C-X-C motif chemokine receptor 4 (CXCR4)), administering the donor cells to the subject, and then selectively inhibiting host cells in the subject based on their expression of the second isoform of the target protein, thereby improving engraftment of donor cells in the subject. Also provided are combinations for administration to a subject in need thereof, wherein the combination comprises (1) a population of donor cells modified to express a first isoform of a target protein (e.g., CXCR4) and (2) an antagonist (e.g., anti-CXCR4 antigen-binding protein) that specifically binds to a second isoform of the target protein but does not specifically bind to the first isoform of the target protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
Methods can be conducted to prevent disulfide scrambling in liquid chromatography-mass spectrometry analysis of a protein of interest. In particular, methods can be conducted by employing a NEM analog, such as maleimide, and a heavy isotope counterpart of the NEM analog, such as a heavy isotope substituted maleimide, to alkylate a protein of interest and to alkylate a peptide digest of the protein of interest under conditions that prevent disulfide scrambling and subjecting the samples to a liquid chromatography-mass spectrometry analysis.
The present disclosure generally relates to the treatment of subjects having liver disease or metabolic disorder or at risk of developing liver disease or metabolic disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
56.
TREATMENT OF MUSCLE DISORDER WITH FOLLICULIN INTERACTING PROTEIN 1 (FNIP1) INHIBITORS AND/OR FOLLICULIN (FLCN) INHIBITORS
The present disclosure generally relates to the treatment of subjects having muscle disorder or at risk of developing muscle disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A fixture for an automatic needle injection is disclosed, wherein the fixture comprises a housing including a chamber, the housing including a first plurality of walls, a second plurality of walls, and a third plurality of walls, a holder, and a membrane; wherein the membrane is contained in the holder, the holder is secured within a portion of the housing, and the holder is configured to allow a portion of a needle of a syringe to pass through a portion of the holder and into the chamber of the housing.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
58.
METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY
The present invention generally pertains to methods for characterizing the fragment crystallizable (Fc) region of a bispecific antibody (bsAb) using Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS).
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
59.
Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors
The present disclosure generally relates to the treatment of subjects having muscle disorder or at risk of developing muscle disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A fixture for an automatic needle injection is disclosed, wherein the fixture comprises a housing including a chamber, the housing including a first plurality of walls, a second plurality of walls, and a third plurality of walls, a holder, and a membrane; wherein the membrane is contained in the holder, the holder is secured within a portion of the housing, and the holder is configured to allow a portion of a needle of a syringe to pass through a portion of the holder and into the chamber of the housing.
Institute for Research in Biomedicine (IRB) (Switzerland)
Inventor
Murphy, Andrew J.
Stevens, Sean
Rathinam, Chozhavendan
Eynon, Elizabeth
Manz, Markus
Flavell, Richard
Yancopoulos, George D.
Abstract
Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.
The present disclosure provides methods for enriching, identifying, and/or characterizing at least one host cell protein (HCP) impurity in a sample containing a viral vector. The HCP impurities can be enriched through the utilization of a library of bead-based peptide ligands. The enriched HCPs can subsequently be subjected to enzymatic digestion, generating peptides which can be identified by liquid chromatography-mass spectrometry (LC-MS) analysis to specifically identify and/or characterize said at least one HCP impurity.
The present disclosure provides antibodies that bind to C-X-C Motif Chemokine Receptor 4 (CXCR4), and methods of use. In various embodiments of the disclosure, the antibodies are fully human antibodies that specifically bind to CXCR4. In some embodiments, the antibodies of the disclosure are useful for inhibiting activation of CXCR4 activity, thus providing a means of affecting the chemotaxis of blood cells and/or immune cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Combination drug delivery devices sold full containing pharmaceutical preparations for the treatment of retinal diseases Combination drug delivery devices sold empty for the treatment of retinal diseases
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
68.
AUTOMATION-ENABLED METHODS FOR CHARACTERIZING NON-CONSENSUS N- AND O-GLYCANS IN PROTEINS
The present invention generally pertains to methods of characterizing non-consensus glycosylation sites of a protein. In particular, the present invention pertains to the use of high-throughput automated processes through digestion, enrichment of glycopeptides by liquid chromatography-mass spectrometry for identifying identification of non-consensus glycosylation sites.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.
The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
71.
BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
Provided herein are bispecific antibodies that bind to both a capsid of an AAV particle and to transferrin receptor (TfR) or calcium voltage-gated channel auxiliary subunit gamma 1 (CACNG1), related molecular complexes, and pharmaceutical compositions, and methods of use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
A61P 43/00 - Drugs for specific purposes, not provided for in groups
72.
ASPARAGINE FEED STRATEGIES TO IMPROVE CELL CULTURE PERFORMANCE AND MITIGATE ASPARAGINE SEQUENCE VARIANTS
A method for culturing eukaryotic cells for improved cell culture performance is provided. The method generally comprises propagating or maintaining eukaryotic cells in a defined cell culture medium; wherein the defined cell culture medium is supplemented with asparagine in an amount from about 2.6 mM to about 43.2 mM during early fed-batch cell culture and from about 2.6 mM to about 21.6 mM during late fed-batch cell culture; and maintaining said cells in said asparagine supplemented cell culture medium for at least a portion of the early fed-batch cell culture and at least a portion of the late fed-batch cell culture; wherein the performance of the cell culture is improved by the asparagine supplementation, as compared to a similar method with a lower amount of asparagine supplementation in the early and/or late fed-batch cell culture.
C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
C12N 1/04 - Preserving or maintaining viable microorganisms
73.
HOST CELL PROTEIN ANALYSIS OF AAV USING PROTEOMINER TECHNOLOGY
The present disclosure provides methods for enriching, identifying, and/or characterizing at least one host cell protein (HCP) impurity in a sample containing a viral vector. The HCP impurities can be enriched through the utilization of a library of bead-based peptide ligands. The enriched HCPs can subsequently be subjected to enzymatic digestion, generating peptides which can be identified by liquid chromatography-mass spectrometry (LC-MS) analysis to specifically identify and/or characterize said at least one HCP impurity.
The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods of improving recombinant protein titer and cell titer in cell culture using cell culture media having reduced impurities are provided, and well as cell culture media having reduced impurities that can used for the production of a recombinant protein and cells with improved titer. The cell culture media having reduced impurities comprises a HEPES buffer, and the reduced impurities are HEPES related impurities. In certain aspects, methods and media improve protein titer, cell growth, and/or viable cell density.
The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy
82.
Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies
B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
83.
NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI
Non-human animal cells and non-human animals comprising a humanized ACE2 locus and a humanized TMPRSS locus, and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized ACE2 locus and a humanized TMPRSS locus express a human ACE2 protein or a chimeric ACE2 protein, fragments of which are from human ACE2; and a human TMPRSS or chimeric TMPRSS protein, fragments of which are from human TMPRSS. Methods are also provided for using such non-human animals comprising a humanized ACE2 locus and a humanized TMPRSS locus to assess in vivo ACE2 activity, e.g., coronavirus infection and/or the treatment or prevention thereof.
Multidomain therapeutic proteins comprising a TfR-binding delivery domain fused to an acid sphingomyelinase polypeptide and nucleic acid constructs and compositions that allow insertion of a multidomain therapeutic protein coding sequence into a target genomic locus such as an endogenous ALB locus and/or expression of the multidomain therapeutic protein coding sequence are provided. The multidomain therapeutic proteins and nucleic acid constructs and compositions can be administered to cells, populations of cells, or subjects and can be used in methods of integration of a multidomain therapeutic protein nucleic acid into a target genomic locus, methods of expression of a multidomain therapeutic protein in a cell, methods of treating acid sphingomyelinase deficiency in a subject, and methods of preventing or reducing the onset of a sign or symptom of acid sphingomyelinase deficiency in a subject.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy.
